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Osteonecrosis of the femoral head is an intractable disease often occurring in patients aged 30–40 years that can
cause femoral head collapse, pain, and gait disturbance. Background factors, including corticosteroid use, alcohol
intake, and idiopathic causes, have been indicated. It is estimated that 70–80 % of osteonecrosis patients experience
femoral head collapse, for which total hip arthroplasty is considered the most effective treatment, even in young patients.
Thus, there is a crucial need for developing a minimally invasive regenerative therapy as a preventive surgery for femoral
head collapse: this has been an important area of research in the past decades. Core decompression, the most popular
minimally invasive surgery for osteonecrosis of the femoral head, has been used for a long time; however, it has been
insufficient to prevent femoral head collapse. For further improvement in therapeutic efficacy, cell transplantation and
the use of artificial bone and growth factors have been proposed in addition to core decompression. Since 2000, newer
therapies such as autologous bone marrow cell transplantation and the embedding of metal implant rods have been
developed in Europe and the USA; however, these approaches have yet to become a global standard. This practical
review summarizes applied state-of-the-art regenerative therapy-based core decompression. We introduce the clinical
application of recombinant human fibroblast growth factor (rhFGF)-2-impregnated gelatin hydrogel for patients with
precollapse osteonecrosis of the femoral head. Radiography and computed tomography have confirmed bone
regeneration inside the femoral heads around the region of rhFGF-2 gelatin hydrogel administration. With further
development, the minimally invasive method, which can be expected to promote bone regeneration in necrotic
areas, could become a useful early-stage treatment for osteonecrosis of the femoral head. Patients can resume
their daily routine soon after surgery, and the procedure is inexpensive. As such, it is a promising regenerative
therapy that can be actively employed in osteonecrosis of the femoral head before femoral head collapse.
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Osteonecrosis of the femoral head (ONFH) is a destruc-
tive disease of the hip joint caused by a critical decrease
in the vascular supply to the femoral head. Several
causative factors have been indicated, including cortico-
steroid use, alcohol intake, hypercoagulation, bone mar-
row fat embolisms, elevation of intraosseous pressure in
the femoral head, and vascular endothelial dysfunction
[1–4]. However, the pathogenesis of ONFH is poorly
understood. ONFH often occurs in young adults who* Correspondence: ykuromd@kuhp.kyoto-u.ac.jp
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the Creative Commons license, and indicate ifare in their 30s, and it occurs bilaterally in approxi-
mately half of the cases. Steroid-induced ONFH is com-
monly encountered by orthopedic surgeons and in other
medical departments (such as collagen disease, rheuma-
tology, hematology, nephrology, transplant surgery, re-
spiratory, dermatology, and ophthalmology departments)
where steroid pulse therapies are performed. Thus, mag-
netic resonance imaging (MRI) can be performed for
early diagnosis, especially for patients receiving steroid
pulse therapy.
Core decompression, which is frequently used in
Europe and the USA [2, 3, 5], is a minimally invasive
surgery; however, if the necrotic area is large, the effect
of core decompression may be limited, and femoral headis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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never performed in Japan, except for biopsy purposes.
Other conventional joint-preserving therapies, such as
trochanteric rotational osteotomy (the most common hip
joint surgery in Japan) and vascularized bone grafts, are
difficult, highly invasive, and entail several months of
recovery before the patient can resume a daily routine.
Considering the age at which ONFH commonly occurs,
opting for such operations while the patient is still
asymptomatic is difficult. Both the patients and surgeons
have difficulty in deciding on a method and the timing of
these operations.
Femoral head collapse occurs in 70–80 % of ONFH
cases, depending on the size and location [6, 7]. After fem-
oral head collapse, the ONFH site develops secondary
osteoarthritis (OA), destroying both the femoral head and
the acetabulum [2, 3, 8]. Total hip arthroplasty (THA) is
considered an effective treatment for secondary osteoarth-
ritis, even in young patients [3, 7]. As THA is invasive and
requires a revision surgery, it is crucial to develop a min-
imally invasive regenerative therapy that can preserve the
femoral head, thus preventing collapse. This has been a
research focus for many years [2, 3, 9–11].
Cell therapy [12–16], proteins, and other bone substi-
tutes [9, 17, 18] have been proposed, and various types
of cell therapies using autologous marrow cells or stem
cells are already being attempted, though they have not
yet become standardized. Non-cellular therapeutic strat-
egies using growth factors have also been proposed;
however, verification in animal experiments has made
little progress, primarily because of the absence of an
animal model for femoral head-specific necrosis [9, 19, 20]
and secondarily because of the lack of a technique to
locally deliver the growth factor [21].
To help address this problem, we reported a new rabbit
model in which early ONFH progresses to femoral head
collapse and OA, similar to that in humans. While animal
models of corticosteroid treatment alone do not develop
the characteristics of advanced ONFH seen in humans [22],
we applied a rabbit model of ONFH induced by a combin-
ation of methylprednisolone administration and vascular
occlusion of the capital femoral epiphysis by electro-
coagulation. The rabbits started to develop ONFH around
4 weeks after the ONFH procedure and established ONFH
within 8 weeks [23]. In this model, we showed that a
single local injection of recombinant human fibroblast
growth factor (rhFGF)-2-impregnated gelatin hydrogel,
which has superior slow-release characteristics, suppresses
the progression of femoral head necrosis. To translate this
research to humans, the clinical application of controlled
release rhFGF-2 for precollapse ONFH patients was
performed at the Department of Orthopaedic Surgery
in Kyoto University Hospital starting in March 2013 [24].
In this review article, we present the local application ofrhFGF-2 in human ONFH and its clinical benefit com-
pared to other treatments.
Treatment strategy for ONFH
Conventional surgical treatment, mainly core decompres-
sion, is used widely in Europe and the USA [2, 3, 5]; in
contrast, in Japan, a variety of surgical osteotomy proce-
dures have been performed. However, clinical results vary:
the collapse rate of the femoral head was more than 70 %
in core decompression with precollapse ONFH in one
study [13], while others have reported a collapse rate of
50 % with rotational osteotomy [25]. A variety of surgical
methods have also been reported, including free or
vascularized methods with fibular and iliac bone grafts,
allogeneic bone grafts, and bone cartilage transplantation
(mosaicplasty); bone cement injection to the femoral head
has also been reported, although it is not common.
Currently, there is no consensus regarding the standard
treatment (Fig. 1).
The use of MRI improves early diagnosis, especially in
patients receiving steroid pulse therapy. Accordingly, the
treatment target has emphasized aggressive early preven-
tion of femoral head collapse. Core decompression alone
is challenging [13, 26, 27]; therefore, cell transplantation
and artificial bone or metal implants in the core site have
also been attempted. In addition, a deliverable, growth
factor-containing, bone-promoting substitute has also
been proposed [2, 3, 9, 17, 18].
Osteotomy
Over 40 years, various types of osteotomies have been
performed for the treatment of ONFH. The concept of
surgery consists of moving the necrotic region from the
weight-bearing surface of the femoral head. These involve
three-axis directions, varus-valgus, flexion-extension, and
anterior-posterior rotation. These procedures are technic-
ally demanding and are popular in Asia, though less in
other regions [3, 28].
Bone grafting
Various surgical techniques have been reported for the
use of bone grafts for the treatment of ONFH. In the
1930s, Phemister first reported a surgical procedure of a
non-vascularized bone graft from the tibia for the treat-
ment of ONFH [28]. Since then, newer techniques such
as the lightbulb and trapdoor non-vascularized bone graft
have been used with good results [29]. Another technique
for bone grafting is vascularized option. Vascularized
fibular graft was introduced in 1979 and consists of a
fibular graft together with its vascular supply and har-
vested directly into the necrotic lesion of the femoral
head [28]. Vascularized fibular graft is one of the tech-
nically difficult orthopedic surgeries which require
technique of microvascular surgery. More recently, the
Fig. 1 Treatment strategy for osteonecrosis of the femoral head. Scheme of treatment strategy for osteonecrosis of the femoral head (ONFH) is
shown. In daily clinical cases, even if a patient is diagnosed with ONFH, most cases experience femoral head collapse without surgical treatments
and finally have to undergo total hip arthroplasty. The ultimate goal for ONFH therapy is to prevent femoral head collapse. Surgical alternatives
for preservation include osteotomy and vascularized bone grafting, but the procedures are difficult, technically demanding, and require long-term
hospitalization. Therefore, there has been a great desire for a minimally invasive regenerative therapy that can prevent femoral head collapse.
Several regenerative treatment options, including cell or stem cell transplantation, artificial bone substitutes, and administration of growth and
differentiation factors, have been recently reported
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results [30].
Pure conservative therapy
A recent prospective, double-blind study showed that
with conservative therapy using an oral bisphosphonate
agent to prevent femoral head collapse, there was no dif-
ference in collapse progress between the placebo and
treatment groups [31]. In Japan, novel clinical trials as a
pure conservative therapy are performed and are regis-
tered to the public Japanese clinical trials registry, the
University Hospital Medical Information Network (UMIN)
Clinical Trials Registry. In recent years, bisphosphonates
and parathyroid hormone have also started to be used
to prevent collapse (UMIN000017582). In addition, for
systemic lupus erythematosus patients undergoing ster-
oid pulse therapy, a three-drug combination of the enzyme
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tor (pitavastatin), adenosine diphosphate receptor blocking
antiplatelet (clopidogrel), and antioxidant (tocopherol)
is co-administered (UMIN000008230). Other types of
conservative treatment using an external device, such
as hyperbaric oxygen therapy and extracorporeal shock
wave lithotrity (UMIN000020197), have also been de-
veloped [32].
Core decompression
Core decompression is a minimally invasive surgery for
ONFH dating back to the 1960s [28]. It was originally
used to create a single large bone hole >10-mm diameter
and had a high femoral head collapse rate. Over time,the method improved and now involves multiple bone
holes of a smaller diameter (3 mm); this method has
been popular since the 2000s. With the improved method,
collapse rates are now 30 % for precollapse ONFH [33].
To further improve therapeutic efficacy to prevent femoral
head collapse, cell transplantation, artificial bone, and
growth factors have been used (Fig. 2).
Regenerative therapy-based core decompression
Metal implants
A preventive treatment involving the placement of cy-
lindrical artifacts in the core decompression site has
been developed in Europe and the USA. Such artifacts
include implant rods made of Zimmer Trabecular Metal
(porous tantalum, manufactured by Zimmer, Warsaw, IN,
USA), which are available in both small and large diame-
ters. Tsao et al. used a large-diameter rod in 113 joints
from 97 patients with precollapse ONFH; over 4 years, 19
joints (19.6 %) underwent THA [34]. Similarly, Veillette
et al. reported that of 48 joints from 42 patients, 16 (33.3 %)
experienced a collapsed femoral head over 4 years [35]. In
addition, Floerkemeier et al. reported that in 23 joints with
ONFH, 13 (56.5 %) required THA after an average of
1.45 years. In contrast to other studies, the outcome after
core decompression combined with tantalum rod inser-
tion was not superior compared to core decompression
alone [36].
Artificial bones
Yu et al. reported that injectable calcium phosphate-based
artificial bone (CaSO4/CaPO4 composite) was used alone
Fig. 2 Regenerative therapy using controlled release of recombinant human fibroblast growth factor. Schematic views and photographs of
the surgical procedure using recombinant human fibroblast growth factor (rhFGF)-2-impregnated gelatin hydrogel for patients with precollapse
stage of osteonecrosis of the femoral head (ONFH) are shown. a A schema of the surgical procedure administering the rhFGF-2 gelatin hydrogel.
The rhFGF-2-impregnated gelatin hydrogel is embedded percutaneously over the lateral aspect of the femur near the level of the lesser trochanter.
A small photograph on the left side shows the actual gelatin hydrogel, which is a superior slow-release carrier for growth factors. b A representative
intraoperative fluoroscopic image at drilling. c A screenshot of the preoperative planning using navigation software is shown. The yellow area shows
the area of ONFH. The surgeon planned the suitable route of drilling (blue screw)
Table 1 Joint-preserving regenerative therapy-based core decompression

















Floerkemeier [36] 2011/P CD 23 NR 40 1.4 43.5
TR
Yu [37] 2015/P CD 6 S 5, A 68, I 21, T 5 48 1.4 50.0
CaSO4/CaPO4
Hernigou [16] 2009/P CD 534 S 19, SCD 31, I 28 39 13.0 82.4
BMMNC
Gangji [13] 2011/RCT CD 11 S 82, A 9, I 9 45.7 5.0 27.3
Gangji [13] 2011/RCT CD 13 S 85, A 8, I 8 42.2 5.0 76.9
BMMNC
Civinini [41] 2012/P CD, BMC, 30 S 49, A 35, I 16 43.9 1.7 83.3
CaSO4/CaPO4
Yamasaki [42] 2010/R CD 9 S 22, A 44, I 33 49 2.4 0
HA
Yamasaki [42] 2010/R CD, BMMNC, 27 S 73, A 20, I 7 41 2.4 56.7
HA
Lieberman [17] 2004/P CD, FBG 16 S 76, A 18, S&A 6 47 4.4 87.5
rhBMP 50 mg
Papanagiotou [43] 2014/P CD, FBG 5 S 40, A 20, I 40 32 4.0 80.0
rhBMP 3.5 g
Kuroda [23] 2015/P CD 10 S 80, A 20 39.8 1.0 90.0
rhFGF-2 800 μg
P prospective study, R retrospective study, RCT randomized clinical trial, CD core decompression, TR tantalum rod, BMMNC bone marrow mononuclear cell,
BMC bone marrow cell, HA hydroxyapatite, FBG fibular bone graft, rhBMP recombinant human bone morphogenetic protein, ONFH osteonecrosis of the femoral head,
S steroid use, A alcohol intake, I idiopathic, T trauma, NR not reported, SCD sickle cell disease
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with precollapse ONFH and 8/13 joints (61.5 %) with early
collapsed ONFH were reported to have undergone THA
after an average of 8.5 months post-surgery [37].
Cell transplantation
In ONFH, progression of the necrotic area and occurrence
of additional necrotic areas are extremely rare [38]. There-
fore, regeneration of the necrotic bone to normal bone tis-
sue could make it possible to cure ONFH. To regenerate
the necrotic bone, there is a need to promote remodeling
and angiogenesis as well as absorption of the necrotic
bone. However, clinical results for free bone grafts do not
indicate significant improvement over core decompres-
sion. Thus, a new treatment strategy has been attempted
in which cell transplantation, such as autologous bone
marrow mononuclear cells, was employed to regenerate
the necrotic bone directly. As reported by Hernigou and
Beaujean, bone marrow was taken from the iliac crest, and
the mononuclear cell-containing fraction was separated
using a cell centrifugal separation device [12]. The cells
were injected into the necrotic bone area from the core
decompression site that promotes the remodeling ofa
c
Post-
Fig. 3 Planning and representative computed tomography images. a A scree
image shows a bone defect at the drilling route and implanted region 1 day
osteonecrotic area of the femoral head. c In contrast, apparent bone regenera
(yellow arrow). The normal contour of the femoral head is maintained. d Appa
implanted region (yellow arrow) and drilling route (yellow arrowheads) at 2 ye
regeneration of the drilling route can be observedcancellous bone regeneration and necrosis. After
8–18 years, only 94 of the 534 patients (17.6 %) with
precollapse ONFH were reported to have femoral head
collapse [16]. In addition, Gangji et al. conducted a
prospective double-blind study on 24 hips, in which
core decompression and autologous bone marrow mono-
nuclear cell transplantation combination were com-
pared over 5 years. Progress and structural destruction
of the subchondral bone were noted in 8 of the 11
joints (72.7 %) in the core decompression group and in 3
of the 13 joints (23.1 %) in the combination group [13].
Furthermore, in a systematic review, Papakostidis et al.
reported that in the precollapse stage, core decompression
with autologous bone marrow cell implantation into the
femoral head is clinically effective and can improve
survivorship of the femoral heads and reduce the need for
THA [39]. Another systemic review by Lau et al.
reported that cell therapy is considered a reliable regen-
erative approach to engraft more cells in the necrotic
area and that further development of a method promot-
ing differentiation is needed [40].
In combination with cell therapy, the use of artificial




nshot of the preoperative planning. b Coronal computed tomography
postoperatively. The yellow dashed line shows the border of the
tion of the osteonecrotic area is observed at 1 year postoperatively
rent bone regeneration of the osteonecrotic area is observed in the
ars postoperatively. Normal contour, thick trabecular bone, and bone
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with a combination of bone marrow cell transplantation
and artificial bone, 5/30 joints (16.6 %) with precollapse
ONFH and 3/7 joints (42.8 %) with early collapsed ONFH
further collapsed or progressed further an average of
20.6 months post-surgery [41]. Yamasaki et al. reported
that 30 joints from 22 patients received transplanted bone
marrow mononuclear cells with interconnected porous
calcium hydroxyapatite into the femoral head; over an
average of 29 months, 13 (43.3 %) experienced femoral
head collapse [42].
Autologous bone marrow cell transplantation may be
reliable in early-stage ONFH patients [12, 13, 16, 39, 40].
Ex vivo amplification of bone marrow cells has been
proposed to increase the number of injected stem
cells [13–15, 30].
Growth factors
Bone regeneration in joint areas using cell growth fac-
tors, another treatment approach, has become an im-
portant topic of research. Problems with protein therapy
include an extremely short half-life and side effects with
systemic or high-dose administration. The use of rhFGF-
2-impregnated gelatin hydrogel has the advantage of
sustained release over rhFGF-2 solution because its bio-
logic half-life period is short [21]. A slow-release system
built around a bioabsorbable gelatin hydrogel enables locala b
d e
Fig. 4 Representative magnetic resonance images. a Preoperative coronal
of the femoral head (ONFH) that occupied the weight-bearing portion and
area and the femoral neck region 6 months and 1 year postoperatively, sho
traumatic procedure. e MRI scan 18 months postoperatively, showing the f
the femoral neck is changing to the normal signal intensity of the bone. f
signal intensity at the ONFH area. The area and size of ONFH decreased atadministration with excellent controlled release, greatly
contributing to establishing practical use for protein ther-
apy. Such factors useful for bone regeneration include
transforming growth factor-β, bone morphogenetic pro-
tein (BMP), FGF-2, vascular endothelial growth factor, and
insulin-like growth factor [2, 3, 9]. For ONFH, the use of
BMP in combination with bone grafts has been reported.
For example, Lieberman et al. co-administered rhBMP
(50 mg) with an allogeneic fibular graft after core de-
compression. Of 16 cases with precollapse ONFH, two
(12.5 %) collapsed after an average of 53 months [17].
Moreover, Papanagiotou et al. co-administered rhBMP
3.5 mg with an autologous fibular graft; of five cases
with precollapse ONFH, one (20 %) experienced fem-
oral head collapse over an average of 4 years [43].
In the field of bone and joint medicine, the angiogenic
and osteogenic actions of rhFGF-2 have been the subject
of numerous reports [21, 23, 24, 44, 45]. In particular,
the use of gelatin hydrogel as a superior slow-release
carrier has produced increased bone mass in areas of
bone deficit [21]. Furthermore, rhFGF-2 administration
produced rapid osteogenesis and increased bone mass in
humans with lower leg fracture [44] and osteotomy sur-
face [45]. A strategy using growth factors has also been
proposed to treat ONFH. We reported the first clinical
application of rhFGF-2-impregnated gelatin hydrogel for
patients with precollapse stage of ONFH (Fig. 2) [24].c
f
2 years
T1-weighted magnetic resonance imaging (MRI) showing osteonecrosis
extended laterally to the acetabular edge. b–d MRI scan of the ONFH
wing continued low signal intensity, indicating the influence of the
irst change of signal intensity at the drilling route. The drilling site at
Most recent MRI scan 2 years postoperatively, showing almost normal
the weight-bearing surface (yellow arrow)
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2 underwent a single local administration of 800-μg
rhFGF-2-impregnated gelatin hydrogel and followed up
for 1 year. Primary outcomes included adverse events and
complications. Secondary outcomes included changes in
Harris Hip Scores, visual analog scale pain scores, and
UCLA activity rating scores, radiological changes as deter-
mined via radiographs, computed tomography scans, and
MRI of the hip joint. One-year short-term results of this
pilot study indicated the approach was safe and feasible.
During 1-year follow-up of 10 patients, there was only one
case of femoral head collapse; however, this occurred in a
hip with extensive necrosis. Stage progression and collapse
did not occur in the other nine cases. The results of
previous joint-preserving regenerative therapy-based core
decompression are presented in Table 1.
The minimally invasive therapy (1-cm skin incision)
attempted to prevent femoral head collapse through
direct administration of rhFGF-2, which has both angio-
genic and osteogenic actions. Computed tomography
(Fig. 3) and recent MRI (Fig. 4) confirmed bone regener-
ation and reduction of the necrotic area. Additionally,
hospitalization costs were dramatically reduced to 10 %
of that for THA. From an economic standpoint, avoiding
the need for artificial joints could greatly reduce medical
expenses. However, it is still unclear whether rhFGF-2
administration or conservative treatment has a better
efficacy. Further studies with longer follow-up are
needed to analyze and evaluate the survival rates of
femoral heads treated with rhFGF-2 administration or
conservative treatment.Conclusions
The most recent regenerative therapy for ONFH has
aimed to induce bone regeneration to prevent femoral
head collapse. To develop the practical clinical application
for regenerative ONFH therapies, suitable sources, includ-
ing cell sources, artificial materials, specific proteins, or
combinations thereof, must be identified. With the use of
various regenerative therapies, including cell therapy, im-
plants, and recombinant growth factors, the treatment for
ONFH will reach a turning point in the near future.Consent for publication
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